Display options
Cite
Woodward M, Marko A, Galea S, et al. Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data. Open Forum Infect Dis. 2019;6(8)doi: 10.1093/ofid/ofz295.
Woodward, M., Marko, A., Galea, S., Eagel, B., & Straus, W. (2019). Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data. Open forum infectious diseases, 6(8), . https://doi.org/10.1093/ofid/ofz295
Woodward, Meredith, et al. "Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data." Open forum infectious diseases vol. 6,8 (2019). doi: https://doi.org/10.1093/ofid/ofz295
Woodward M, Marko A, Galea S, Eagel B, Straus W. Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data. Open Forum Infect Dis. 2019 Aug 01;6(8). doi: 10.1093/ofid/ofz295. PMID: 31392326; PMCID: PMC6685817.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2019 Aug 01;6(8). doi: 10.1093/ofid/ofz295.

Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data.

Open forum infectious diseases

Meredith Woodward, Ann Marko, Susan Galea, Barry Eagel, Walter Straus

Affiliations

  1. Merck & Co., Inc., Kenilworth, New Jersey.

PMID: 31392326 PMCID: PMC6685817 DOI: 10.1093/ofid/ofz295

Abstract

BACKGROUND: Varicella, a contagious infectious disease caused by varicella zoster virus (VZV), can result in hospitalization and, occasionally, death. Varicella virus vaccine live (VVVL [VARIVAX]) was introduced in the United States in 1995.

METHODS: This comprehensive review of the VVVL safety profile is based on 22 years of postmarketing adverse event (AE) data received through spontaneous and noninterventional study reports submitted by health care providers and on a review of the published literature (cumulatively from March 17, 1995, through March 16, 2017, during which period >212 million doses were distributed globally).

RESULTS: The VVVL safety profile was consistent with previous publications, with common AEs including varicella, rash, and pyrexia. AE reports have decreased over time, from ~500 per million doses in 1995 to ~40 per million doses in 2016; serious AEs comprise 0.8 reports per million doses. Secondary transmission was rare (8 confirmed cases); polymerase chain reaction analysis indicated that 38 of the 66 reported potential secondary transmission cases of varicella were attributable to wild-type VZV. The prevalence of major birth defects in the Pregnancy Registry was similar to that in the general US population. In total, 86 cases of death were reported after vaccination with VVVL; immunocompromised individuals appeared to be most at risk for a fatal varicella- or herpes zoster-related outcome.

CONCLUSIONS: This comprehensive 22-year review confirms the overall safety profile for VVVL, with no new safety concerns identified. Since VVVL's introduction in 1995, notable declines in varicella cases and in varicella-related deaths have occurred compared with the prevaccination period.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords: postmarketing; safety; varicella; varicella vaccine; varicella zoster vaccine

References

  1. Vaccine. 2000 Nov 22;19(7-8):916-23 - PubMed
  2. Lancet. 1952 Sep 20;2(6734):549-54 - PubMed
  3. J Virol. 1992 Feb;66(2):1016-20 - PubMed
  4. MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40 - PubMed
  5. MMWR Morb Mortal Wkly Rep. 2008 Jan 11;57(1):1-5 - PubMed
  6. J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9 - PubMed
  7. Pediatrics. 1977 Jan;59(1):3-7 - PubMed
  8. Birth Defects Res A Clin Mol Teratol. 2009 Jan;85(1):20-9 - PubMed
  9. Pediatr Infect Dis J. 2011 Mar;30(3):266-8 - PubMed
  10. Vaccine. 2012 Aug 24;30(39):5791-8 - PubMed
  11. Semin Pediatr Neurol. 2012 Sep;19(3):124-9 - PubMed
  12. Ther Adv Vaccines. 2014 Mar;2(2):39-55 - PubMed
  13. MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):732-3 - PubMed
  14. Hum Vaccin Immunother. 2015;11(1):91-4 - PubMed
  15. J Pediatric Infect Dis Soc. 2016 Dec;5(4):395-402 - PubMed
  16. Hum Vaccin Immunother. 2016 Mar 3;12(3):651-4 - PubMed
  17. Pediatrics. 2016 Mar;137(3):e20153741 - PubMed
  18. MMWR Morb Mortal Wkly Rep. 2016 Sep 02;65(34):902-5 - PubMed
  19. PLoS Pathog. 2016 Oct 20;12(10):e1005892 - PubMed
  20. Expert Rev Vaccines. 2017 Apr;16(4):391-400 - PubMed
  21. Vaccine. 2017 Apr 25;35(18):2351-2357 - PubMed
  22. Vaccine. 2017 Dec 19;35(52):7231-7239 - PubMed
  23. Hum Vaccin Immunother. 2018;14(10):2460-2463 - PubMed
  24. Pediatrics. 1986 Oct;78(4 Pt 2):748-56 - PubMed

Publication Types